News

While Cystic Fibrosis is considered to be a rare, “orphan” disease, affecting about 70,000 people in total worldwide, the support community that surrounds it is significantly larger, and works tirelessly to support fundraising and advocacy for the disease. Now, a new initiative by one of the world’s leading CF advocacy…

OrPro Therapeutics, Inc. is presenting the newest data concerning its leading pre-clinical therapeutic, ORP-100, at the 28th Annual North American Cystic Fibrosis Conference held October 9-11 in Atlanta. ORP-100 is being developed to treat cystic fibrosis by attacking the pathological, adhesive mucus found in patients’ lungs. According to a…

Case Western Reserve University faculty and clinicians are among those this weekend commemorating the discovery 25 years ago of the transmembrane conductance Cystic Fibrosis gene (CFTR) and reflecting on subsequent treatment advances that stemmed from the genetic breakthrough a quarter-century ago. The discovery was acheived in 1989 by a…

Belgium-based clinical-stage biotech, Galapagos, recently presented the findings of its novel and complementary corrector series that modulates the cystic fibrosis transmembrane conductance regulator (CFTR) at the North American Cystic Fibrosis Conference (NACFC) in Atlanta. During the two sessions led by Dr. Katja Conrath, the company disclosed preclinical data…

One of the approaches to developing novel treatments for difficult-to-manage conditions such as cystic fibrosis (CF) is taking FDA-approved, well-studied therapies and combining them with other drugs to produce more effective formulations. Along these lines, Vertex Pharmaceuticals has just announced several of their upcoming research and…

Cystic Fibrosis (CF), one of the most common genetic diseases among Caucasian children, is classified as an orphan disease, estimated to affect roughly 70,000 individuals worldwide, 30,000 of which live in the United States. While there are several subsidies that cater to research and development…

European leader in Data Driven Medicine, Sophia Genetics, has just launched a first-of-its-kind cystic fibrosis transmembrane conductance regulator (CFTR) in vitro diagnostic (IVD) solution, which will allow doctors to conduct complete CF studies in one next-generation sequencing trial. By providing a complete study of CFTR variants in a single NGS experiment, the company’s…

The non-profit organization Cystic Fibrosis Research, Inc. (CFRI) is organizing a wine tasting event to help support research to find a cure for cystic fibrosis (CF), taking place on Sunday, October 19, between 3 and 7 pm at the Purple Orchid Wine Country Resort & Spa.

The British Gene Therapy Consortium announced recently that it has decided not to attend the upcoming North American Cystic Fibrosis Conference (NACFC), where they were planning on presenting the latest data about their Multidose Gene Therapy (Wave 1) Trial, which focuses on developing a genetic treatment for cystic fibrosis (CF).

A new study entitled “Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study” published in October issue of BMC Pulmonary Medicine suggests that self-reported exercise improves nutritional and pulmonary outcomes in adults with cystic fibrosis. Cystic Fibrosis is a life-threatening disease, characterized…